Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs
eLife · 22.07.2025 · 13
DOI: 10.7554/elife.93170 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 22.07.2025. Verfasst von Huanhuan Joyce Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Meyer Cancer Center, Weill Cornell Medicine, New York, United States. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Small Cell Lung Carcinoma, Proto-Oncogene Proteins c-myc, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense Education Activity, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
We previously described our initial efforts to develop a model for small cell lung cancer (SCLC) derived from human embryonic stem cells (hESCs) that were differentiated to form pulmonary neuroendocrine cells (PNECs), a putative cell of origin for neuroendocrine-positive SCLC. Although reduced expression of the tumor suppressor genes TP53 and RB1 allowed the induced PNECs to form subcutaneous growths in immune-deficient mice, the tumors did not display the aggressive characteristics of SCLC seen in human patients. Here, we report that the additional, doxycycline-regulated expression of a transgene encoding wild-type or mutant MYC protein promotes rapid growth, invasion, and metastasis of these hESC-derived cells after injection into the renal capsule. Similar to others, we find that the addition of MYC encourages the formation of the SCLC-N subtype, marked by high levels of NEUROD1 RNA. Using paired primary and metastatic samples for RNA-sequencing, we observe that the subtype of SCLC does not change upon metastatic spread and that production of NEUROD1 is maintained. We also describe histological features of these malignant, SCLC-like tumors derived from hESCs and discuss potential uses of this model in efforts to control and better understand this recalcitrant neoplasm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meyer Cancer Center, Weill Cornell Medicine, New York, United States.
- The Pritzker School of Molecular Engineering, The University of Chicago, Chicago, United States.
- The Ben May Department for Cancer Research, The University of Chicago, Chicago, United States.
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, United States.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States.
- Institute for Computational Biomedicine, Weill Cornell Medicine, New York, United States.
ORCID-Profile: Huanhuan Joyce Chen, Eric E Gardner, Abhimanyu Thakur
Förderung
- Department of Defense Education Activity
- NCI NIH HHS
- NIH HHS
- Lung Cancer Research Foundation
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Chen, H. J., Gardner, E. E., Shah, Y., Zhang, K., Thakur, A., Zhang, C., Elemento, O., & Varmus, H. (2025). Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs. eLife, 13. https://doi.org/10.7554/elife.93170
Vancouver
Chen HJ, Gardner EE, Shah Y, Zhang K, Thakur A, Zhang C, et al. Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs. eLife. 2025;13. doi:10.7554/elife.93170
BibTeX
@article{Chen2025,
author = {Chen, Huanhuan Joyce and Gardner, Eric E and Shah, Yajas and Zhang, Kui and Thakur, Abhimanyu and Zhang, Chen and Elemento, Olivier and Varmus, Harold},
title = {Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs},
journal = {eLife},
year = {2025},
volume = {13},
doi = {10.7554/elife.93170}
}
EUVIMED